nodes	percent_of_prediction	percent_of_DWPC	metapath
Imipramine—SLC22A1—hematologic cancer	0.162	0.775	CbGaD
Imipramine—ABCB1—hematologic cancer	0.0472	0.225	CbGaD
Imipramine—SLC22A3—Melphalan—hematologic cancer	0.0352	0.0718	CbGbCtD
Imipramine—CYP2C18—Ifosfamide—hematologic cancer	0.0194	0.0396	CbGbCtD
Imipramine—SLC22A2—Daunorubicin—hematologic cancer	0.0147	0.0301	CbGbCtD
Imipramine—ORM1—Imatinib—hematologic cancer	0.0137	0.0279	CbGbCtD
Imipramine—SLC22A2—Cytarabine—hematologic cancer	0.013	0.0265	CbGbCtD
Imipramine—SLC22A2—Cladribine—hematologic cancer	0.0123	0.0251	CbGbCtD
Imipramine—SLC22A3—Irinotecan—hematologic cancer	0.0119	0.0243	CbGbCtD
Imipramine—SLC22A1—Cytarabine—hematologic cancer	0.0113	0.0231	CbGbCtD
Imipramine—SLC22A2—Imatinib—hematologic cancer	0.0113	0.023	CbGbCtD
Imipramine—CYP1A2—Anagrelide—hematologic cancer	0.011	0.0225	CbGbCtD
Imipramine—CYP2B6—Thiotepa—hematologic cancer	0.0108	0.0221	CbGbCtD
Imipramine—SLC22A1—Cladribine—hematologic cancer	0.0107	0.0218	CbGbCtD
Imipramine—SLC22A3—Vincristine—hematologic cancer	0.0104	0.0213	CbGbCtD
Imipramine—SLC22A1—Imatinib—hematologic cancer	0.00981	0.02	CbGbCtD
Imipramine—CYP2E1—Thalidomide—hematologic cancer	0.00707	0.0144	CbGbCtD
Imipramine—ABCB1—Lenalidomide—hematologic cancer	0.00669	0.0137	CbGbCtD
Imipramine—CYP3A7—Ifosfamide—hematologic cancer	0.00645	0.0132	CbGbCtD
Imipramine—CYP3A7-CYP3A51P—Ifosfamide—hematologic cancer	0.00645	0.0132	CbGbCtD
Imipramine—SLC22A2—Vinblastine—hematologic cancer	0.00627	0.0128	CbGbCtD
Imipramine—CYP3A7—Imatinib—hematologic cancer	0.00616	0.0126	CbGbCtD
Imipramine—CYP3A7-CYP3A51P—Imatinib—hematologic cancer	0.00616	0.0126	CbGbCtD
Imipramine—CYP2B6—Ifosfamide—hematologic cancer	0.00614	0.0125	CbGbCtD
Imipramine—CYP2E1—Dacarbazine—hematologic cancer	0.00608	0.0124	CbGbCtD
Imipramine—CYP2D6—Lomustine—hematologic cancer	0.00586	0.012	CbGbCtD
Imipramine—CYP1A2—Carmustine—hematologic cancer	0.0058	0.0118	CbGbCtD
Imipramine—SLC22A2—Cisplatin—hematologic cancer	0.00575	0.0117	CbGbCtD
Imipramine—CYP2B6—Nilotinib—hematologic cancer	0.00533	0.0109	CbGbCtD
Imipramine—CYP2D6—Idarubicin—hematologic cancer	0.00523	0.0107	CbGbCtD
Imipramine—CYP2C19—Bortezomib—hematologic cancer	0.00509	0.0104	CbGbCtD
Imipramine—CYP1A2—Methoxsalen—hematologic cancer	0.00493	0.0101	CbGbCtD
Imipramine—CYP2E1—Mitoxantrone—hematologic cancer	0.00472	0.00962	CbGbCtD
Imipramine—CYP1A2—Bortezomib—hematologic cancer	0.00469	0.00957	CbGbCtD
Imipramine—CYP1A2—Daunorubicin—hematologic cancer	0.00449	0.00916	CbGbCtD
Imipramine—CYP2D6—Hydroxyurea—hematologic cancer	0.00444	0.00907	CbGbCtD
Imipramine—CYP2C19—Thalidomide—hematologic cancer	0.00443	0.00904	CbGbCtD
Imipramine—CYP1A2—Alitretinoin—hematologic cancer	0.0044	0.00897	CbGbCtD
Imipramine—CYP2C19—Teniposide—hematologic cancer	0.00423	0.00862	CbGbCtD
Imipramine—CYP1A2—Thalidomide—hematologic cancer	0.00409	0.00834	CbGbCtD
Imipramine—CYP3A4—Bexarotene—hematologic cancer	0.00401	0.00818	CbGbCtD
Imipramine—ABCB1—Daunorubicin—hematologic cancer	0.00392	0.00801	CbGbCtD
Imipramine—CYP2C19—Ifosfamide—hematologic cancer	0.0039	0.00796	CbGbCtD
Imipramine—CYP2D6—Bortezomib—hematologic cancer	0.00387	0.00789	CbGbCtD
Imipramine—CYP3A7-CYP3A51P—Irinotecan—hematologic cancer	0.00385	0.00785	CbGbCtD
Imipramine—CYP3A7—Irinotecan—hematologic cancer	0.00385	0.00785	CbGbCtD
Imipramine—ABCB1—Alitretinoin—hematologic cancer	0.00384	0.00784	CbGbCtD
Imipramine—CYP3A4—Lomustine—hematologic cancer	0.00373	0.00761	CbGbCtD
Imipramine—CYP3A4—Busulfan—hematologic cancer	0.00373	0.00761	CbGbCtD
Imipramine—CYP2C19—Imatinib—hematologic cancer	0.00373	0.0076	CbGbCtD
Imipramine—CYP2B6—Irinotecan—hematologic cancer	0.00366	0.00747	CbGbCtD
Imipramine—CYP1A2—Dacarbazine—hematologic cancer	0.00352	0.00717	CbGbCtD
Imipramine—CYP1A2—Imatinib—hematologic cancer	0.00344	0.00701	CbGbCtD
Imipramine—CYP3A7—Vincristine—hematologic cancer	0.00336	0.00686	CbGbCtD
Imipramine—CYP3A7-CYP3A51P—Vincristine—hematologic cancer	0.00336	0.00686	CbGbCtD
Imipramine—CYP3A4—Thiotepa—hematologic cancer	0.00332	0.00678	CbGbCtD
Imipramine—ABCB1—Imatinib—hematologic cancer	0.00301	0.00613	CbGbCtD
Imipramine—CYP2B6—Cisplatin—hematologic cancer	0.00299	0.00609	CbGbCtD
Imipramine—CYP2E1—Etoposide—hematologic cancer	0.00297	0.00607	CbGbCtD
Imipramine—CYP2D6—Imatinib—hematologic cancer	0.00283	0.00578	CbGbCtD
Imipramine—CYP1A2—Dasatinib—hematologic cancer	0.00276	0.00563	CbGbCtD
Imipramine—ABCB1—Nilotinib—hematologic cancer	0.00273	0.00557	CbGbCtD
Imipramine—ABCB1—Vinorelbine—hematologic cancer	0.00271	0.00553	CbGbCtD
Imipramine—CYP3A4—Methoxsalen—hematologic cancer	0.00258	0.00527	CbGbCtD
Imipramine—CYP2D6—Nilotinib—hematologic cancer	0.00257	0.00525	CbGbCtD
Imipramine—CYP2D6—Vinorelbine—hematologic cancer	0.00255	0.00521	CbGbCtD
Imipramine—CYP3A7-CYP3A51P—Dexamethasone—hematologic cancer	0.00253	0.00517	CbGbCtD
Imipramine—CYP3A7—Dexamethasone—hematologic cancer	0.00253	0.00517	CbGbCtD
Imipramine—CYP3A4—Bortezomib—hematologic cancer	0.00246	0.00502	CbGbCtD
Imipramine—CYP2C19—Prednisone—hematologic cancer	0.00245	0.00501	CbGbCtD
Imipramine—CYP2E1—Dexamethasone—hematologic cancer	0.00244	0.00499	CbGbCtD
Imipramine—ABCB1—Dasatinib—hematologic cancer	0.00241	0.00493	CbGbCtD
Imipramine—CYP2B6—Dexamethasone—hematologic cancer	0.00241	0.00492	CbGbCtD
Imipramine—ABCB1—Mitoxantrone—hematologic cancer	0.00238	0.00487	CbGbCtD
Imipramine—CYP3A4—Daunorubicin—hematologic cancer	0.00235	0.0048	CbGbCtD
Imipramine—ABCB1—Betamethasone—hematologic cancer	0.00213	0.00434	CbGbCtD
Imipramine—ABCB1—Gemcitabine—hematologic cancer	0.00211	0.0043	CbGbCtD
Imipramine—ABCB1—Prednisolone—hematologic cancer	0.0021	0.00428	CbGbCtD
Imipramine—CYP3A4—Cytarabine—hematologic cancer	0.00207	0.00423	CbGbCtD
Imipramine—CYP3A4—Teniposide—hematologic cancer	0.00204	0.00417	CbGbCtD
Imipramine—CYP2B6—Doxorubicin—hematologic cancer	0.002	0.00408	CbGbCtD
Imipramine—ABCB1—Prednisone—hematologic cancer	0.00198	0.00404	CbGbCtD
Imipramine—CYP3A4—Ifosfamide—hematologic cancer	0.00189	0.00385	CbGbCtD
Imipramine—ABCB1—Irinotecan—hematologic cancer	0.00188	0.00383	CbGbCtD
Imipramine—CYP3A4—Imatinib—hematologic cancer	0.0018	0.00367	CbGbCtD
Imipramine—CYP1A2—Etoposide—hematologic cancer	0.00172	0.00351	CbGbCtD
Imipramine—CYP3A4—Ruxolitinib—hematologic cancer	0.0017	0.00346	CbGbCtD
Imipramine—ABCB1—Vinblastine—hematologic cancer	0.00167	0.00341	CbGbCtD
Imipramine—ABCB1—Vincristine—hematologic cancer	0.00164	0.00335	CbGbCtD
Imipramine—CYP3A4—Nilotinib—hematologic cancer	0.00164	0.00334	CbGbCtD
Imipramine—CYP3A4—Vinorelbine—hematologic cancer	0.00162	0.00331	CbGbCtD
Imipramine—CYP2D6—Vinblastine—hematologic cancer	0.00157	0.00321	CbGbCtD
Imipramine—CYP2C19—Dexamethasone—hematologic cancer	0.00153	0.00313	CbGbCtD
Imipramine—ABCB1—Cisplatin—hematologic cancer	0.00153	0.00312	CbGbCtD
Imipramine—ABCB1—Etoposide—hematologic cancer	0.0015	0.00307	CbGbCtD
Imipramine—CYP3A4—Triamcinolone—hematologic cancer	0.00148	0.00303	CbGbCtD
Imipramine—CYP3A4—Dasatinib—hematologic cancer	0.00145	0.00295	CbGbCtD
Imipramine—CYP3A4—Mitoxantrone—hematologic cancer	0.00143	0.00292	CbGbCtD
Imipramine—CYP3A4—Betamethasone—hematologic cancer	0.00127	0.0026	CbGbCtD
Imipramine—CYP3A4—Prednisolone—hematologic cancer	0.00126	0.00256	CbGbCtD
Imipramine—ABCB1—Dexamethasone—hematologic cancer	0.00124	0.00252	CbGbCtD
Imipramine—CYP3A4—Prednisone—hematologic cancer	0.00119	0.00242	CbGbCtD
Imipramine—CYP2D6—Dexamethasone—hematologic cancer	0.00117	0.00238	CbGbCtD
Imipramine—CYP3A4—Irinotecan—hematologic cancer	0.00112	0.0023	CbGbCtD
Imipramine—ABCB1—Doxorubicin—hematologic cancer	0.00103	0.00209	CbGbCtD
Imipramine—CYP3A4—Vinblastine—hematologic cancer	0.001	0.00204	CbGbCtD
Imipramine—ABCB1—Methotrexate—hematologic cancer	0.000994	0.00203	CbGbCtD
Imipramine—CYP3A4—Vincristine—hematologic cancer	0.000983	0.00201	CbGbCtD
Imipramine—CYP2D6—Doxorubicin—hematologic cancer	0.000966	0.00197	CbGbCtD
Imipramine—CYP3A4—Etoposide—hematologic cancer	0.000901	0.00184	CbGbCtD
Imipramine—KCND2—testis—hematologic cancer	0.000768	0.029	CbGeAlD
Imipramine—CYP3A4—Dexamethasone—hematologic cancer	0.000741	0.00151	CbGbCtD
Imipramine—KCND3—lung—hematologic cancer	0.000709	0.0268	CbGeAlD
Imipramine—ORM1—hematopoietic system—hematologic cancer	0.000669	0.0252	CbGeAlD
Imipramine—KCND3—testis—hematologic cancer	0.000669	0.0252	CbGeAlD
Imipramine—CHRM4—testis—hematologic cancer	0.000638	0.024	CbGeAlD
Imipramine—SLC6A3—hematopoietic system—hematologic cancer	0.000623	0.0235	CbGeAlD
Imipramine—CYP3A4—Doxorubicin—hematologic cancer	0.000615	0.00125	CbGbCtD
Imipramine—SLC22A3—hematopoietic system—hematologic cancer	0.000586	0.0221	CbGeAlD
Imipramine—SLC6A4—hematopoietic system—hematologic cancer	0.00057	0.0215	CbGeAlD
Imipramine—HTR1A—hematopoietic system—hematologic cancer	0.000507	0.0191	CbGeAlD
Imipramine—KCND3—lymph node—hematologic cancer	0.000485	0.0183	CbGeAlD
Imipramine—HTR7—hematopoietic system—hematologic cancer	0.000484	0.0183	CbGeAlD
Imipramine—CYP2C19—hematopoietic system—hematologic cancer	0.000473	0.0178	CbGeAlD
Imipramine—ADRA1A—hematopoietic system—hematologic cancer	0.000467	0.0176	CbGeAlD
Imipramine—KCNH2—hematopoietic system—hematologic cancer	0.000451	0.017	CbGeAlD
Imipramine—SLC22A3—gonad—hematologic cancer	0.000446	0.0168	CbGeAlD
Imipramine—ORM1—blood—hematologic cancer	0.000444	0.0167	CbGeAlD
Imipramine—ORM1—bone marrow—hematologic cancer	0.000429	0.0162	CbGeAlD
Imipramine—SLC22A4—blood—hematologic cancer	0.000427	0.0161	CbGeAlD
Imipramine—SLC22A4—bone marrow—hematologic cancer	0.000413	0.0156	CbGeAlD
Imipramine—SLC22A1—blood—hematologic cancer	0.000406	0.0153	CbGeAlD
Imipramine—ORM1—lung—hematologic cancer	0.000389	0.0147	CbGeAlD
Imipramine—CYP1A2—hematopoietic system—hematologic cancer	0.000386	0.0146	CbGeAlD
Imipramine—SLC6A2—gonad—hematologic cancer	0.000382	0.0144	CbGeAlD
Imipramine—SLC6A4—blood—hematologic cancer	0.000378	0.0143	CbGeAlD
Imipramine—SLC22A4—lung—hematologic cancer	0.000374	0.0141	CbGeAlD
Imipramine—CYP2B6—hematopoietic system—hematologic cancer	0.00037	0.014	CbGeAlD
Imipramine—HTR7—gonad—hematologic cancer	0.000368	0.0139	CbGeAlD
Imipramine—SLC6A3—lung—hematologic cancer	0.000362	0.0136	CbGeAlD
Imipramine—HRH1—hematopoietic system—hematologic cancer	0.000361	0.0136	CbGeAlD
Imipramine—CYP2E1—hematopoietic system—hematologic cancer	0.000347	0.0131	CbGeAlD
Imipramine—SLC6A3—testis—hematologic cancer	0.000341	0.0129	CbGeAlD
Imipramine—SLC22A3—lung—hematologic cancer	0.00034	0.0128	CbGeAlD
Imipramine—SLC6A4—lung—hematologic cancer	0.000331	0.0125	CbGeAlD
Imipramine—CHRM1—lung—hematologic cancer	0.00033	0.0124	CbGeAlD
Imipramine—SLC22A3—testis—hematologic cancer	0.000321	0.0121	CbGeAlD
Imipramine—HTR7—blood—hematologic cancer	0.000321	0.0121	CbGeAlD
Imipramine—CYP2C19—blood—hematologic cancer	0.000313	0.0118	CbGeAlD
Imipramine—ADRA1A—blood—hematologic cancer	0.000309	0.0117	CbGeAlD
Imipramine—HTR2A—hematopoietic system—hematologic cancer	0.000302	0.0114	CbGeAlD
Imipramine—KCNH2—blood—hematologic cancer	0.000299	0.0113	CbGeAlD
Imipramine—SLC6A2—lung—hematologic cancer	0.000292	0.011	CbGeAlD
Imipramine—KCNH2—bone marrow—hematologic cancer	0.000289	0.0109	CbGeAlD
Imipramine—CYP2B6—gonad—hematologic cancer	0.000281	0.0106	CbGeAlD
Imipramine—HTR7—lung—hematologic cancer	0.000281	0.0106	CbGeAlD
Imipramine—CYP3A4—hematopoietic system—hematologic cancer	0.000279	0.0105	CbGeAlD
Imipramine—CHRM3—testis—hematologic cancer	0.000279	0.0105	CbGeAlD
Imipramine—SLC6A2—testis—hematologic cancer	0.000275	0.0104	CbGeAlD
Imipramine—CYP2D6—hematopoietic system—hematologic cancer	0.000275	0.0104	CbGeAlD
Imipramine—ORM1—lymph node—hematologic cancer	0.000266	0.01	CbGeAlD
Imipramine—DRD2—lung—hematologic cancer	0.000266	0.01	CbGeAlD
Imipramine—HTR7—testis—hematologic cancer	0.000265	0.01	CbGeAlD
Imipramine—SLC22A4—lymph node—hematologic cancer	0.000256	0.00965	CbGeAlD
Imipramine—CYP1A2—blood—hematologic cancer	0.000256	0.00965	CbGeAlD
Imipramine—DRD2—testis—hematologic cancer	0.000251	0.00946	CbGeAlD
Imipramine—KCNH2—testis—hematologic cancer	0.000247	0.00932	CbGeAlD
Imipramine—CYP2B6—blood—hematologic cancer	0.000245	0.00925	CbGeAlD
Imipramine—SLC22A3—lymph node—hematologic cancer	0.000233	0.00878	CbGeAlD
Imipramine—CYP2E1—blood—hematologic cancer	0.00023	0.00868	CbGeAlD
Imipramine—HTR2A—gonad—hematologic cancer	0.00023	0.00866	CbGeAlD
Imipramine—CYP1A2—lung—hematologic cancer	0.000224	0.00846	CbGeAlD
Imipramine—CYP2B6—lung—hematologic cancer	0.000215	0.00811	CbGeAlD
Imipramine—HRH1—lung—hematologic cancer	0.00021	0.00792	CbGeAlD
Imipramine—Benazepril—MTHFR—hematologic cancer	0.000207	0.134	CrCbGaD
Imipramine—CYP2B6—testis—hematologic cancer	0.000203	0.00765	CbGeAlD
Imipramine—CYP2E1—lung—hematologic cancer	0.000202	0.00761	CbGeAlD
Imipramine—HTR2A—blood—hematologic cancer	0.0002	0.00754	CbGeAlD
Imipramine—SLC6A2—lymph node—hematologic cancer	0.000199	0.00752	CbGeAlD
Imipramine—HRH1—testis—hematologic cancer	0.000198	0.00747	CbGeAlD
Imipramine—ABCB1—hematopoietic system—hematologic cancer	0.000198	0.00746	CbGeAlD
Imipramine—CYP2E1—testis—hematologic cancer	0.00019	0.00718	CbGeAlD
Imipramine—CYP3A4—blood—hematologic cancer	0.000185	0.00698	CbGeAlD
Imipramine—CYP2D6—blood—hematologic cancer	0.000182	0.00687	CbGeAlD
Imipramine—KCNH2—lymph node—hematologic cancer	0.000179	0.00675	CbGeAlD
Imipramine—HTR2A—lung—hematologic cancer	0.000175	0.00661	CbGeAlD
Imipramine—HTR2A—testis—hematologic cancer	0.000165	0.00624	CbGeAlD
Imipramine—CYP2D6—testis—hematologic cancer	0.000151	0.00568	CbGeAlD
Imipramine—ABCB1—gonad—hematologic cancer	0.00015	0.00567	CbGeAlD
Imipramine—HRH1—lymph node—hematologic cancer	0.000144	0.00541	CbGeAlD
Imipramine—ABCB1—blood—hematologic cancer	0.000131	0.00494	CbGeAlD
Imipramine—Acepromazine—SLC22A1—hematologic cancer	0.00013	0.0841	CrCbGaD
Imipramine—Thioproperazine—SLC22A1—hematologic cancer	0.000127	0.0822	CrCbGaD
Imipramine—ABCB1—bone marrow—hematologic cancer	0.000127	0.00478	CbGeAlD
Imipramine—Pipotiazine—SLC22A1—hematologic cancer	0.000125	0.0809	CrCbGaD
Imipramine—ABCB1—lung—hematologic cancer	0.000115	0.00433	CbGeAlD
Imipramine—ABCB1—testis—hematologic cancer	0.000108	0.00409	CbGeAlD
Imipramine—Clomipramine—GSTP1—hematologic cancer	0.000107	0.0691	CrCbGaD
Imipramine—Diphenhydramine—SLC22A1—hematologic cancer	8.96e-05	0.0578	CrCbGaD
Imipramine—Desipramine—SLC22A1—hematologic cancer	7.98e-05	0.0514	CrCbGaD
Imipramine—ABCB1—lymph node—hematologic cancer	7.86e-05	0.00296	CbGeAlD
Imipramine—Chlorpromazine—SLC22A1—hematologic cancer	6.8e-05	0.0439	CrCbGaD
Imipramine—Epinastine—ABCB1—hematologic cancer	5.45e-05	0.0351	CrCbGaD
Imipramine—Oxcarbazepine—ALB—hematologic cancer	5.26e-05	0.0339	CrCbGaD
Imipramine—Maprotiline—ABCB1—hematologic cancer	4.69e-05	0.0302	CrCbGaD
Imipramine—Triflupromazine—ABCB1—hematologic cancer	4.1e-05	0.0264	CrCbGaD
Imipramine—Acepromazine—ALB—hematologic cancer	3.97e-05	0.0256	CrCbGaD
Imipramine—Thioproperazine—ALB—hematologic cancer	3.88e-05	0.0251	CrCbGaD
Imipramine—Pipotiazine—ALB—hematologic cancer	3.82e-05	0.0246	CrCbGaD
Imipramine—Carbamazepine—ABCB1—hematologic cancer	3.42e-05	0.0221	CrCbGaD
Imipramine—Clomipramine—ALB—hematologic cancer	3.02e-05	0.0195	CrCbGaD
Imipramine—Nortriptyline—ALB—hematologic cancer	2.95e-05	0.019	CrCbGaD
Imipramine—Clomipramine—ABCB1—hematologic cancer	2.88e-05	0.0186	CrCbGaD
Imipramine—Trimipramine—ABCB1—hematologic cancer	2.65e-05	0.0171	CrCbGaD
Imipramine—Promethazine—ABCB1—hematologic cancer	2.55e-05	0.0165	CrCbGaD
Imipramine—Doxepin—ABCB1—hematologic cancer	2.53e-05	0.0163	CrCbGaD
Imipramine—Desipramine—ABCB1—hematologic cancer	2.32e-05	0.015	CrCbGaD
Imipramine—Urticaria—Triamcinolone—hematologic cancer	2.14e-05	0.000116	CcSEcCtD
Imipramine—Dysgeusia—Methotrexate—hematologic cancer	2.14e-05	0.000116	CcSEcCtD
Imipramine—Asthenia—Etoposide—hematologic cancer	2.13e-05	0.000116	CcSEcCtD
Imipramine—Body temperature increased—Triamcinolone—hematologic cancer	2.13e-05	0.000116	CcSEcCtD
Imipramine—Anaphylactic shock—Prednisone—hematologic cancer	2.13e-05	0.000116	CcSEcCtD
Imipramine—Oedema—Prednisone—hematologic cancer	2.13e-05	0.000116	CcSEcCtD
Imipramine—Angiopathy—Epirubicin—hematologic cancer	2.13e-05	0.000116	CcSEcCtD
Imipramine—Urethral disorder—Doxorubicin—hematologic cancer	2.13e-05	0.000116	CcSEcCtD
Imipramine—Decreased appetite—Betamethasone—hematologic cancer	2.13e-05	0.000115	CcSEcCtD
Imipramine—Decreased appetite—Dexamethasone—hematologic cancer	2.13e-05	0.000115	CcSEcCtD
Imipramine—Nausea—Irinotecan—hematologic cancer	2.12e-05	0.000115	CcSEcCtD
Imipramine—Nausea—Mitoxantrone—hematologic cancer	2.12e-05	0.000115	CcSEcCtD
Imipramine—Immune system disorder—Epirubicin—hematologic cancer	2.12e-05	0.000115	CcSEcCtD
Imipramine—Infection—Prednisone—hematologic cancer	2.12e-05	0.000115	CcSEcCtD
Imipramine—Mediastinal disorder—Epirubicin—hematologic cancer	2.11e-05	0.000115	CcSEcCtD
Imipramine—Gastrointestinal disorder—Betamethasone—hematologic cancer	2.11e-05	0.000115	CcSEcCtD
Imipramine—Gastrointestinal disorder—Dexamethasone—hematologic cancer	2.11e-05	0.000115	CcSEcCtD
Imipramine—Fatigue—Dexamethasone—hematologic cancer	2.11e-05	0.000115	CcSEcCtD
Imipramine—Fatigue—Betamethasone—hematologic cancer	2.11e-05	0.000115	CcSEcCtD
Imipramine—Pruritus—Etoposide—hematologic cancer	2.1e-05	0.000114	CcSEcCtD
Imipramine—Shock—Prednisone—hematologic cancer	2.1e-05	0.000114	CcSEcCtD
Imipramine—Arrhythmia—Epirubicin—hematologic cancer	2.09e-05	0.000114	CcSEcCtD
Imipramine—Nervous system disorder—Prednisone—hematologic cancer	2.09e-05	0.000113	CcSEcCtD
Imipramine—Tachycardia—Prednisone—hematologic cancer	2.08e-05	0.000113	CcSEcCtD
Imipramine—Chlorpromazine—ALB—hematologic cancer	2.07e-05	0.0134	CrCbGaD
Imipramine—Alopecia—Epirubicin—hematologic cancer	2.07e-05	0.000113	CcSEcCtD
Imipramine—Skin disorder—Prednisone—hematologic cancer	2.07e-05	0.000112	CcSEcCtD
Imipramine—Nausea—Gemcitabine—hematologic cancer	2.07e-05	0.000112	CcSEcCtD
Imipramine—Vomiting—Cisplatin—hematologic cancer	2.06e-05	0.000112	CcSEcCtD
Imipramine—Hyperhidrosis—Prednisone—hematologic cancer	2.06e-05	0.000112	CcSEcCtD
Imipramine—Vision blurred—Methotrexate—hematologic cancer	2.06e-05	0.000112	CcSEcCtD
Imipramine—Mental disorder—Epirubicin—hematologic cancer	2.05e-05	0.000112	CcSEcCtD
Imipramine—Amitriptyline—ALB—hematologic cancer	2.05e-05	0.0132	CrCbGaD
Imipramine—Rash—Cisplatin—hematologic cancer	2.04e-05	0.000111	CcSEcCtD
Imipramine—Dermatitis—Cisplatin—hematologic cancer	2.04e-05	0.000111	CcSEcCtD
Imipramine—Malnutrition—Epirubicin—hematologic cancer	2.04e-05	0.000111	CcSEcCtD
Imipramine—Diarrhoea—Etoposide—hematologic cancer	2.03e-05	0.00011	CcSEcCtD
Imipramine—Anorexia—Prednisone—hematologic cancer	2.03e-05	0.00011	CcSEcCtD
Imipramine—Eye disorder—Doxorubicin—hematologic cancer	2.03e-05	0.00011	CcSEcCtD
Imipramine—Ill-defined disorder—Methotrexate—hematologic cancer	2.02e-05	0.00011	CcSEcCtD
Imipramine—Tinnitus—Doxorubicin—hematologic cancer	2.02e-05	0.00011	CcSEcCtD
Imipramine—Feeling abnormal—Dexamethasone—hematologic cancer	2.02e-05	0.000109	CcSEcCtD
Imipramine—Feeling abnormal—Betamethasone—hematologic cancer	2.02e-05	0.000109	CcSEcCtD
Imipramine—Flushing—Doxorubicin—hematologic cancer	2.01e-05	0.000109	CcSEcCtD
Imipramine—Cardiac disorder—Doxorubicin—hematologic cancer	2.01e-05	0.000109	CcSEcCtD
Imipramine—Tension—Epirubicin—hematologic cancer	2e-05	0.000109	CcSEcCtD
Imipramine—Gastrointestinal pain—Dexamethasone—hematologic cancer	2e-05	0.000109	CcSEcCtD
Imipramine—Gastrointestinal pain—Betamethasone—hematologic cancer	2e-05	0.000109	CcSEcCtD
Imipramine—Dysgeusia—Epirubicin—hematologic cancer	2e-05	0.000109	CcSEcCtD
Imipramine—Nervousness—Epirubicin—hematologic cancer	1.98e-05	0.000108	CcSEcCtD
Imipramine—Chlorpromazine—ABCB1—hematologic cancer	1.98e-05	0.0128	CrCbGaD
Imipramine—Angiopathy—Doxorubicin—hematologic cancer	1.97e-05	0.000107	CcSEcCtD
Imipramine—Malaise—Methotrexate—hematologic cancer	1.97e-05	0.000107	CcSEcCtD
Imipramine—Dizziness—Etoposide—hematologic cancer	1.96e-05	0.000107	CcSEcCtD
Imipramine—Immune system disorder—Doxorubicin—hematologic cancer	1.96e-05	0.000106	CcSEcCtD
Imipramine—Mediastinal disorder—Doxorubicin—hematologic cancer	1.95e-05	0.000106	CcSEcCtD
Imipramine—Amitriptyline—ABCB1—hematologic cancer	1.95e-05	0.0126	CrCbGaD
Imipramine—Leukopenia—Methotrexate—hematologic cancer	1.95e-05	0.000106	CcSEcCtD
Imipramine—Urticaria—Betamethasone—hematologic cancer	1.94e-05	0.000106	CcSEcCtD
Imipramine—Urticaria—Dexamethasone—hematologic cancer	1.94e-05	0.000106	CcSEcCtD
Imipramine—Dizziness—Prednisolone—hematologic cancer	1.94e-05	0.000105	CcSEcCtD
Imipramine—Arrhythmia—Doxorubicin—hematologic cancer	1.94e-05	0.000105	CcSEcCtD
Imipramine—Asthenia—Triamcinolone—hematologic cancer	1.93e-05	0.000105	CcSEcCtD
Imipramine—Abdominal pain—Betamethasone—hematologic cancer	1.93e-05	0.000105	CcSEcCtD
Imipramine—Body temperature increased—Dexamethasone—hematologic cancer	1.93e-05	0.000105	CcSEcCtD
Imipramine—Body temperature increased—Betamethasone—hematologic cancer	1.93e-05	0.000105	CcSEcCtD
Imipramine—Abdominal pain—Dexamethasone—hematologic cancer	1.93e-05	0.000105	CcSEcCtD
Imipramine—Nausea—Cisplatin—hematologic cancer	1.93e-05	0.000105	CcSEcCtD
Imipramine—Insomnia—Prednisone—hematologic cancer	1.93e-05	0.000105	CcSEcCtD
Imipramine—Vision blurred—Epirubicin—hematologic cancer	1.92e-05	0.000104	CcSEcCtD
Imipramine—Alopecia—Doxorubicin—hematologic cancer	1.92e-05	0.000104	CcSEcCtD
Imipramine—Paraesthesia—Prednisone—hematologic cancer	1.91e-05	0.000104	CcSEcCtD
Imipramine—Pruritus—Triamcinolone—hematologic cancer	1.91e-05	0.000104	CcSEcCtD
Imipramine—Mental disorder—Doxorubicin—hematologic cancer	1.9e-05	0.000103	CcSEcCtD
Imipramine—Ill-defined disorder—Epirubicin—hematologic cancer	1.89e-05	0.000103	CcSEcCtD
Imipramine—Convulsion—Methotrexate—hematologic cancer	1.89e-05	0.000103	CcSEcCtD
Imipramine—Vomiting—Etoposide—hematologic cancer	1.89e-05	0.000103	CcSEcCtD
Imipramine—Malnutrition—Doxorubicin—hematologic cancer	1.89e-05	0.000103	CcSEcCtD
Imipramine—Agitation—Epirubicin—hematologic cancer	1.88e-05	0.000102	CcSEcCtD
Imipramine—Dyspepsia—Prednisone—hematologic cancer	1.87e-05	0.000102	CcSEcCtD
Imipramine—Rash—Etoposide—hematologic cancer	1.87e-05	0.000102	CcSEcCtD
Imipramine—Dermatitis—Etoposide—hematologic cancer	1.87e-05	0.000102	CcSEcCtD
Imipramine—Headache—Etoposide—hematologic cancer	1.86e-05	0.000101	CcSEcCtD
Imipramine—Tension—Doxorubicin—hematologic cancer	1.85e-05	0.000101	CcSEcCtD
Imipramine—Decreased appetite—Prednisone—hematologic cancer	1.85e-05	0.000101	CcSEcCtD
Imipramine—Dysgeusia—Doxorubicin—hematologic cancer	1.85e-05	0.0001	CcSEcCtD
Imipramine—Rash—Prednisolone—hematologic cancer	1.85e-05	0.0001	CcSEcCtD
Imipramine—Dermatitis—Prednisolone—hematologic cancer	1.85e-05	0.0001	CcSEcCtD
Imipramine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	1.84e-05	0.0001	CcSEcCtD
Imipramine—Malaise—Epirubicin—hematologic cancer	1.84e-05	0.0001	CcSEcCtD
Imipramine—Fatigue—Prednisone—hematologic cancer	1.84e-05	9.97e-05	CcSEcCtD
Imipramine—Headache—Prednisolone—hematologic cancer	1.84e-05	9.97e-05	CcSEcCtD
Imipramine—Discomfort—Methotrexate—hematologic cancer	1.83e-05	9.96e-05	CcSEcCtD
Imipramine—Nervousness—Doxorubicin—hematologic cancer	1.83e-05	9.96e-05	CcSEcCtD
Imipramine—Syncope—Epirubicin—hematologic cancer	1.83e-05	9.94e-05	CcSEcCtD
Imipramine—Leukopenia—Epirubicin—hematologic cancer	1.83e-05	9.92e-05	CcSEcCtD
Imipramine—Constipation—Prednisone—hematologic cancer	1.82e-05	9.89e-05	CcSEcCtD
Imipramine—Palpitations—Epirubicin—hematologic cancer	1.8e-05	9.8e-05	CcSEcCtD
Imipramine—Confusional state—Methotrexate—hematologic cancer	1.79e-05	9.75e-05	CcSEcCtD
Imipramine—Loss of consciousness—Epirubicin—hematologic cancer	1.79e-05	9.74e-05	CcSEcCtD
Imipramine—Dizziness—Triamcinolone—hematologic cancer	1.78e-05	9.68e-05	CcSEcCtD
Imipramine—Anaphylactic shock—Methotrexate—hematologic cancer	1.78e-05	9.67e-05	CcSEcCtD
Imipramine—Vision blurred—Doxorubicin—hematologic cancer	1.78e-05	9.67e-05	CcSEcCtD
Imipramine—Convulsion—Epirubicin—hematologic cancer	1.77e-05	9.6e-05	CcSEcCtD
Imipramine—Infection—Methotrexate—hematologic cancer	1.77e-05	9.6e-05	CcSEcCtD
Imipramine—Nausea—Etoposide—hematologic cancer	1.76e-05	9.59e-05	CcSEcCtD
Imipramine—Hypertension—Epirubicin—hematologic cancer	1.76e-05	9.57e-05	CcSEcCtD
Imipramine—Feeling abnormal—Prednisone—hematologic cancer	1.75e-05	9.53e-05	CcSEcCtD
Imipramine—Asthenia—Dexamethasone—hematologic cancer	1.75e-05	9.53e-05	CcSEcCtD
Imipramine—Asthenia—Betamethasone—hematologic cancer	1.75e-05	9.53e-05	CcSEcCtD
Imipramine—Ill-defined disorder—Doxorubicin—hematologic cancer	1.75e-05	9.52e-05	CcSEcCtD
Imipramine—Nervous system disorder—Methotrexate—hematologic cancer	1.75e-05	9.48e-05	CcSEcCtD
Imipramine—Thrombocytopenia—Methotrexate—hematologic cancer	1.74e-05	9.47e-05	CcSEcCtD
Imipramine—Gastrointestinal pain—Prednisone—hematologic cancer	1.74e-05	9.46e-05	CcSEcCtD
Imipramine—Nausea—Prednisolone—hematologic cancer	1.74e-05	9.46e-05	CcSEcCtD
Imipramine—Agitation—Doxorubicin—hematologic cancer	1.74e-05	9.43e-05	CcSEcCtD
Imipramine—Anxiety—Epirubicin—hematologic cancer	1.73e-05	9.41e-05	CcSEcCtD
Imipramine—Pruritus—Betamethasone—hematologic cancer	1.73e-05	9.4e-05	CcSEcCtD
Imipramine—Pruritus—Dexamethasone—hematologic cancer	1.73e-05	9.4e-05	CcSEcCtD
Imipramine—Skin disorder—Methotrexate—hematologic cancer	1.73e-05	9.39e-05	CcSEcCtD
Imipramine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	1.73e-05	9.37e-05	CcSEcCtD
Imipramine—Hyperhidrosis—Methotrexate—hematologic cancer	1.72e-05	9.35e-05	CcSEcCtD
Imipramine—Discomfort—Epirubicin—hematologic cancer	1.72e-05	9.32e-05	CcSEcCtD
Imipramine—Vomiting—Triamcinolone—hematologic cancer	1.71e-05	9.31e-05	CcSEcCtD
Imipramine—Malaise—Doxorubicin—hematologic cancer	1.7e-05	9.25e-05	CcSEcCtD
Imipramine—Rash—Triamcinolone—hematologic cancer	1.7e-05	9.23e-05	CcSEcCtD
Imipramine—Dry mouth—Epirubicin—hematologic cancer	1.7e-05	9.23e-05	CcSEcCtD
Imipramine—Dermatitis—Triamcinolone—hematologic cancer	1.7e-05	9.22e-05	CcSEcCtD
Imipramine—Anorexia—Methotrexate—hematologic cancer	1.7e-05	9.22e-05	CcSEcCtD
Imipramine—Syncope—Doxorubicin—hematologic cancer	1.69e-05	9.2e-05	CcSEcCtD
Imipramine—Urticaria—Prednisone—hematologic cancer	1.69e-05	9.19e-05	CcSEcCtD
Imipramine—Leukopenia—Doxorubicin—hematologic cancer	1.69e-05	9.18e-05	CcSEcCtD
Imipramine—Headache—Triamcinolone—hematologic cancer	1.69e-05	9.17e-05	CcSEcCtD
Imipramine—Abdominal pain—Prednisone—hematologic cancer	1.68e-05	9.14e-05	CcSEcCtD
Imipramine—Body temperature increased—Prednisone—hematologic cancer	1.68e-05	9.14e-05	CcSEcCtD
Imipramine—Confusional state—Epirubicin—hematologic cancer	1.68e-05	9.12e-05	CcSEcCtD
Imipramine—Diarrhoea—Dexamethasone—hematologic cancer	1.67e-05	9.09e-05	CcSEcCtD
Imipramine—Diarrhoea—Betamethasone—hematologic cancer	1.67e-05	9.09e-05	CcSEcCtD
Imipramine—Palpitations—Doxorubicin—hematologic cancer	1.67e-05	9.06e-05	CcSEcCtD
Imipramine—Oedema—Epirubicin—hematologic cancer	1.67e-05	9.05e-05	CcSEcCtD
Imipramine—Anaphylactic shock—Epirubicin—hematologic cancer	1.67e-05	9.05e-05	CcSEcCtD
Imipramine—Loss of consciousness—Doxorubicin—hematologic cancer	1.66e-05	9.02e-05	CcSEcCtD
Imipramine—Infection—Epirubicin—hematologic cancer	1.65e-05	8.99e-05	CcSEcCtD
Imipramine—Shock—Epirubicin—hematologic cancer	1.64e-05	8.9e-05	CcSEcCtD
Imipramine—Convulsion—Doxorubicin—hematologic cancer	1.64e-05	8.89e-05	CcSEcCtD
Imipramine—Nervous system disorder—Epirubicin—hematologic cancer	1.63e-05	8.87e-05	CcSEcCtD
Imipramine—Thrombocytopenia—Epirubicin—hematologic cancer	1.63e-05	8.86e-05	CcSEcCtD
Imipramine—Hypertension—Doxorubicin—hematologic cancer	1.63e-05	8.86e-05	CcSEcCtD
Imipramine—Tachycardia—Epirubicin—hematologic cancer	1.63e-05	8.83e-05	CcSEcCtD
Imipramine—Skin disorder—Epirubicin—hematologic cancer	1.62e-05	8.79e-05	CcSEcCtD
Imipramine—Dizziness—Dexamethasone—hematologic cancer	1.62e-05	8.78e-05	CcSEcCtD
Imipramine—Dizziness—Betamethasone—hematologic cancer	1.62e-05	8.78e-05	CcSEcCtD
Imipramine—Hyperhidrosis—Epirubicin—hematologic cancer	1.61e-05	8.75e-05	CcSEcCtD
Imipramine—Insomnia—Methotrexate—hematologic cancer	1.61e-05	8.74e-05	CcSEcCtD
Imipramine—Anxiety—Doxorubicin—hematologic cancer	1.6e-05	8.7e-05	CcSEcCtD
Imipramine—Nausea—Triamcinolone—hematologic cancer	1.6e-05	8.7e-05	CcSEcCtD
Imipramine—Paraesthesia—Methotrexate—hematologic cancer	1.6e-05	8.68e-05	CcSEcCtD
Imipramine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	1.6e-05	8.67e-05	CcSEcCtD
Imipramine—Discomfort—Doxorubicin—hematologic cancer	1.59e-05	8.63e-05	CcSEcCtD
Imipramine—Anorexia—Epirubicin—hematologic cancer	1.59e-05	8.62e-05	CcSEcCtD
Imipramine—Somnolence—Methotrexate—hematologic cancer	1.58e-05	8.59e-05	CcSEcCtD
Imipramine—Dry mouth—Doxorubicin—hematologic cancer	1.57e-05	8.54e-05	CcSEcCtD
Imipramine—Dyspepsia—Methotrexate—hematologic cancer	1.57e-05	8.51e-05	CcSEcCtD
Imipramine—Vomiting—Betamethasone—hematologic cancer	1.55e-05	8.45e-05	CcSEcCtD
Imipramine—Vomiting—Dexamethasone—hematologic cancer	1.55e-05	8.45e-05	CcSEcCtD
Imipramine—Confusional state—Doxorubicin—hematologic cancer	1.55e-05	8.44e-05	CcSEcCtD
Imipramine—Decreased appetite—Methotrexate—hematologic cancer	1.55e-05	8.4e-05	CcSEcCtD
Imipramine—Rash—Betamethasone—hematologic cancer	1.54e-05	8.38e-05	CcSEcCtD
Imipramine—Rash—Dexamethasone—hematologic cancer	1.54e-05	8.38e-05	CcSEcCtD
Imipramine—Anaphylactic shock—Doxorubicin—hematologic cancer	1.54e-05	8.37e-05	CcSEcCtD
Imipramine—Oedema—Doxorubicin—hematologic cancer	1.54e-05	8.37e-05	CcSEcCtD
Imipramine—Dermatitis—Betamethasone—hematologic cancer	1.54e-05	8.37e-05	CcSEcCtD
Imipramine—Dermatitis—Dexamethasone—hematologic cancer	1.54e-05	8.37e-05	CcSEcCtD
Imipramine—Gastrointestinal disorder—Methotrexate—hematologic cancer	1.54e-05	8.35e-05	CcSEcCtD
Imipramine—Fatigue—Methotrexate—hematologic cancer	1.53e-05	8.34e-05	CcSEcCtD
Imipramine—Headache—Dexamethasone—hematologic cancer	1.53e-05	8.32e-05	CcSEcCtD
Imipramine—Headache—Betamethasone—hematologic cancer	1.53e-05	8.32e-05	CcSEcCtD
Imipramine—Infection—Doxorubicin—hematologic cancer	1.53e-05	8.32e-05	CcSEcCtD
Imipramine—Asthenia—Prednisone—hematologic cancer	1.53e-05	8.3e-05	CcSEcCtD
Imipramine—Shock—Doxorubicin—hematologic cancer	1.52e-05	8.24e-05	CcSEcCtD
Imipramine—Nervous system disorder—Doxorubicin—hematologic cancer	1.51e-05	8.21e-05	CcSEcCtD
Imipramine—Thrombocytopenia—Doxorubicin—hematologic cancer	1.51e-05	8.2e-05	CcSEcCtD
Imipramine—Pruritus—Prednisone—hematologic cancer	1.51e-05	8.18e-05	CcSEcCtD
Imipramine—Insomnia—Epirubicin—hematologic cancer	1.51e-05	8.18e-05	CcSEcCtD
Imipramine—Tachycardia—Doxorubicin—hematologic cancer	1.5e-05	8.17e-05	CcSEcCtD
Imipramine—Skin disorder—Doxorubicin—hematologic cancer	1.5e-05	8.13e-05	CcSEcCtD
Imipramine—Paraesthesia—Epirubicin—hematologic cancer	1.5e-05	8.12e-05	CcSEcCtD
Imipramine—Hyperhidrosis—Doxorubicin—hematologic cancer	1.49e-05	8.09e-05	CcSEcCtD
Imipramine—Somnolence—Epirubicin—hematologic cancer	1.48e-05	8.04e-05	CcSEcCtD
Imipramine—Anorexia—Doxorubicin—hematologic cancer	1.47e-05	7.98e-05	CcSEcCtD
Imipramine—Feeling abnormal—Methotrexate—hematologic cancer	1.47e-05	7.97e-05	CcSEcCtD
Imipramine—Dyspepsia—Epirubicin—hematologic cancer	1.47e-05	7.96e-05	CcSEcCtD
Imipramine—Diarrhoea—Prednisone—hematologic cancer	1.46e-05	7.91e-05	CcSEcCtD
Imipramine—Gastrointestinal pain—Methotrexate—hematologic cancer	1.46e-05	7.91e-05	CcSEcCtD
Imipramine—Nausea—Dexamethasone—hematologic cancer	1.45e-05	7.89e-05	CcSEcCtD
Imipramine—Nausea—Betamethasone—hematologic cancer	1.45e-05	7.89e-05	CcSEcCtD
Imipramine—Decreased appetite—Epirubicin—hematologic cancer	1.45e-05	7.86e-05	CcSEcCtD
Imipramine—Gastrointestinal disorder—Epirubicin—hematologic cancer	1.44e-05	7.81e-05	CcSEcCtD
Imipramine—Fatigue—Epirubicin—hematologic cancer	1.44e-05	7.8e-05	CcSEcCtD
Imipramine—Constipation—Epirubicin—hematologic cancer	1.42e-05	7.74e-05	CcSEcCtD
Imipramine—Urticaria—Methotrexate—hematologic cancer	1.41e-05	7.68e-05	CcSEcCtD
Imipramine—Dizziness—Prednisone—hematologic cancer	1.41e-05	7.65e-05	CcSEcCtD
Imipramine—Abdominal pain—Methotrexate—hematologic cancer	1.41e-05	7.64e-05	CcSEcCtD
Imipramine—Body temperature increased—Methotrexate—hematologic cancer	1.41e-05	7.64e-05	CcSEcCtD
Imipramine—Insomnia—Doxorubicin—hematologic cancer	1.39e-05	7.57e-05	CcSEcCtD
Imipramine—Paraesthesia—Doxorubicin—hematologic cancer	1.38e-05	7.52e-05	CcSEcCtD
Imipramine—Feeling abnormal—Epirubicin—hematologic cancer	1.37e-05	7.46e-05	CcSEcCtD
Imipramine—Somnolence—Doxorubicin—hematologic cancer	1.37e-05	7.44e-05	CcSEcCtD
Imipramine—Gastrointestinal pain—Epirubicin—hematologic cancer	1.36e-05	7.4e-05	CcSEcCtD
Imipramine—Dyspepsia—Doxorubicin—hematologic cancer	1.36e-05	7.37e-05	CcSEcCtD
Imipramine—Vomiting—Prednisone—hematologic cancer	1.35e-05	7.36e-05	CcSEcCtD
Imipramine—Rash—Prednisone—hematologic cancer	1.34e-05	7.29e-05	CcSEcCtD
Imipramine—Dermatitis—Prednisone—hematologic cancer	1.34e-05	7.29e-05	CcSEcCtD
Imipramine—Decreased appetite—Doxorubicin—hematologic cancer	1.34e-05	7.28e-05	CcSEcCtD
Imipramine—Headache—Prednisone—hematologic cancer	1.33e-05	7.25e-05	CcSEcCtD
Imipramine—Gastrointestinal disorder—Doxorubicin—hematologic cancer	1.33e-05	7.23e-05	CcSEcCtD
Imipramine—Fatigue—Doxorubicin—hematologic cancer	1.33e-05	7.22e-05	CcSEcCtD
Imipramine—Urticaria—Epirubicin—hematologic cancer	1.32e-05	7.19e-05	CcSEcCtD
Imipramine—Constipation—Doxorubicin—hematologic cancer	1.32e-05	7.16e-05	CcSEcCtD
Imipramine—Body temperature increased—Epirubicin—hematologic cancer	1.32e-05	7.15e-05	CcSEcCtD
Imipramine—Abdominal pain—Epirubicin—hematologic cancer	1.32e-05	7.15e-05	CcSEcCtD
Imipramine—Asthenia—Methotrexate—hematologic cancer	1.28e-05	6.94e-05	CcSEcCtD
Imipramine—Feeling abnormal—Doxorubicin—hematologic cancer	1.27e-05	6.9e-05	CcSEcCtD
Imipramine—Nausea—Prednisone—hematologic cancer	1.26e-05	6.87e-05	CcSEcCtD
Imipramine—Gastrointestinal pain—Doxorubicin—hematologic cancer	1.26e-05	6.85e-05	CcSEcCtD
Imipramine—Pruritus—Methotrexate—hematologic cancer	1.26e-05	6.84e-05	CcSEcCtD
Imipramine—Urticaria—Doxorubicin—hematologic cancer	1.22e-05	6.65e-05	CcSEcCtD
Imipramine—Abdominal pain—Doxorubicin—hematologic cancer	1.22e-05	6.62e-05	CcSEcCtD
Imipramine—Body temperature increased—Doxorubicin—hematologic cancer	1.22e-05	6.62e-05	CcSEcCtD
Imipramine—Diarrhoea—Methotrexate—hematologic cancer	1.22e-05	6.61e-05	CcSEcCtD
Imipramine—Asthenia—Epirubicin—hematologic cancer	1.19e-05	6.49e-05	CcSEcCtD
Imipramine—Pruritus—Epirubicin—hematologic cancer	1.18e-05	6.4e-05	CcSEcCtD
Imipramine—Dizziness—Methotrexate—hematologic cancer	1.18e-05	6.39e-05	CcSEcCtD
Imipramine—Diarrhoea—Epirubicin—hematologic cancer	1.14e-05	6.19e-05	CcSEcCtD
Imipramine—Vomiting—Methotrexate—hematologic cancer	1.13e-05	6.15e-05	CcSEcCtD
Imipramine—Rash—Methotrexate—hematologic cancer	1.12e-05	6.1e-05	CcSEcCtD
Imipramine—Dermatitis—Methotrexate—hematologic cancer	1.12e-05	6.09e-05	CcSEcCtD
Imipramine—Headache—Methotrexate—hematologic cancer	1.11e-05	6.06e-05	CcSEcCtD
Imipramine—Asthenia—Doxorubicin—hematologic cancer	1.11e-05	6.01e-05	CcSEcCtD
Imipramine—Dizziness—Epirubicin—hematologic cancer	1.1e-05	5.98e-05	CcSEcCtD
Imipramine—Pruritus—Doxorubicin—hematologic cancer	1.09e-05	5.92e-05	CcSEcCtD
Imipramine—Vomiting—Epirubicin—hematologic cancer	1.06e-05	5.75e-05	CcSEcCtD
Imipramine—Nausea—Methotrexate—hematologic cancer	1.06e-05	5.74e-05	CcSEcCtD
Imipramine—Diarrhoea—Doxorubicin—hematologic cancer	1.05e-05	5.73e-05	CcSEcCtD
Imipramine—Rash—Epirubicin—hematologic cancer	1.05e-05	5.7e-05	CcSEcCtD
Imipramine—Dermatitis—Epirubicin—hematologic cancer	1.05e-05	5.7e-05	CcSEcCtD
Imipramine—Headache—Epirubicin—hematologic cancer	1.04e-05	5.67e-05	CcSEcCtD
Imipramine—Dizziness—Doxorubicin—hematologic cancer	1.02e-05	5.54e-05	CcSEcCtD
Imipramine—Nausea—Epirubicin—hematologic cancer	9.89e-06	5.37e-05	CcSEcCtD
Imipramine—Vomiting—Doxorubicin—hematologic cancer	9.8e-06	5.32e-05	CcSEcCtD
Imipramine—Rash—Doxorubicin—hematologic cancer	9.72e-06	5.28e-05	CcSEcCtD
Imipramine—Dermatitis—Doxorubicin—hematologic cancer	9.71e-06	5.27e-05	CcSEcCtD
Imipramine—Headache—Doxorubicin—hematologic cancer	9.65e-06	5.24e-05	CcSEcCtD
Imipramine—Nausea—Doxorubicin—hematologic cancer	9.15e-06	4.97e-05	CcSEcCtD
Imipramine—CYP3A4—Metabolism—GSTP1—hematologic cancer	9.7e-07	1.1e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—JUN—hematologic cancer	9.69e-07	1.1e-05	CbGpPWpGaD
Imipramine—CYP2C19—Metabolism—PIK3CD—hematologic cancer	9.67e-07	1.1e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—SRC—hematologic cancer	9.66e-07	1.1e-05	CbGpPWpGaD
Imipramine—HTR6—Signaling Pathways—HRAS—hematologic cancer	9.65e-07	1.09e-05	CbGpPWpGaD
Imipramine—CYP2B6—Metabolism—PTEN—hematologic cancer	9.64e-07	1.09e-05	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—KRAS—hematologic cancer	9.64e-07	1.09e-05	CbGpPWpGaD
Imipramine—HTR7—Signaling Pathways—HRAS—hematologic cancer	9.64e-07	1.09e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—CDKN1A—hematologic cancer	9.63e-07	1.09e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—CCND1—hematologic cancer	9.62e-07	1.09e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—PTEN—hematologic cancer	9.61e-07	1.09e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—JUN—hematologic cancer	9.6e-07	1.09e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—CCND1—hematologic cancer	9.59e-07	1.09e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—JUN—hematologic cancer	9.57e-07	1.08e-05	CbGpPWpGaD
Imipramine—CYP2C19—Metabolism—ALB—hematologic cancer	9.55e-07	1.08e-05	CbGpPWpGaD
Imipramine—CHRM4—Signaling Pathways—TP53—hematologic cancer	9.52e-07	1.08e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—CDKN1A—hematologic cancer	9.47e-07	1.07e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—CDKN1A—hematologic cancer	9.45e-07	1.07e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—PTEN—hematologic cancer	9.45e-07	1.07e-05	CbGpPWpGaD
Imipramine—CYP2E1—Metabolism—PTEN—hematologic cancer	9.44e-07	1.07e-05	CbGpPWpGaD
Imipramine—ABCB1—Metabolism—PIK3CD—hematologic cancer	9.44e-07	1.07e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—PTEN—hematologic cancer	9.43e-07	1.07e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—CDKN1A—hematologic cancer	9.42e-07	1.07e-05	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—PIK3CA—hematologic cancer	9.42e-07	1.07e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—VEGFA—hematologic cancer	9.41e-07	1.07e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—PTEN—hematologic cancer	9.4e-07	1.07e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—MAPK8—hematologic cancer	9.4e-07	1.07e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—CDKN1A—hematologic cancer	9.39e-07	1.06e-05	CbGpPWpGaD
Imipramine—CYP2D6—Metabolism—CREBBP—hematologic cancer	9.38e-07	1.06e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling by GPCR—AKT1—hematologic cancer	9.37e-07	1.06e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—PTEN—hematologic cancer	9.37e-07	1.06e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—MAPK3—hematologic cancer	9.35e-07	1.06e-05	CbGpPWpGaD
Imipramine—ABCB1—Metabolism—ALB—hematologic cancer	9.32e-07	1.06e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—STAT3—hematologic cancer	9.32e-07	1.06e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—CDKN1A—hematologic cancer	9.3e-07	1.05e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—MAPK3—hematologic cancer	9.3e-07	1.05e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—NRAS—hematologic cancer	9.3e-07	1.05e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—PTEN—hematologic cancer	9.28e-07	1.05e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—CDKN1A—hematologic cancer	9.28e-07	1.05e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—PTEN—hematologic cancer	9.26e-07	1.05e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—MAPK8—hematologic cancer	9.25e-07	1.05e-05	CbGpPWpGaD
Imipramine—HTR6—Signaling Pathways—IL6—hematologic cancer	9.23e-07	1.05e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—MAPK8—hematologic cancer	9.23e-07	1.05e-05	CbGpPWpGaD
Imipramine—HTR7—Signaling Pathways—IL6—hematologic cancer	9.22e-07	1.05e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling by GPCR—AKT1—hematologic cancer	9.22e-07	1.05e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling by GPCR—AKT1—hematologic cancer	9.2e-07	1.04e-05	CbGpPWpGaD
Imipramine—CYP3A7—Metabolism—PIK3CA—hematologic cancer	9.2e-07	1.04e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—MAPK8—hematologic cancer	9.2e-07	1.04e-05	CbGpPWpGaD
Imipramine—CYP2B6—Metabolism—EP300—hematologic cancer	9.2e-07	1.04e-05	CbGpPWpGaD
Imipramine—SLC22A2—Metabolism—PIK3CA—hematologic cancer	9.18e-07	1.04e-05	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—ABCB1—hematologic cancer	9.18e-07	1.04e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling by GPCR—AKT1—hematologic cancer	9.17e-07	1.04e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—MAPK8—hematologic cancer	9.17e-07	1.04e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—EP300—hematologic cancer	9.16e-07	1.04e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling by GPCR—AKT1—hematologic cancer	9.14e-07	1.04e-05	CbGpPWpGaD
Imipramine—CYP2C19—Metabolism—PIK3R1—hematologic cancer	9.14e-07	1.04e-05	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—TP53—hematologic cancer	9.11e-07	1.03e-05	CbGpPWpGaD
Imipramine—CHRM4—Signaling Pathways—HRAS—hematologic cancer	9.1e-07	1.03e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—MYC—hematologic cancer	9.09e-07	1.03e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—MAPK8—hematologic cancer	9.08e-07	1.03e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—TGFB1—hematologic cancer	9.07e-07	1.03e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling by GPCR—AKT1—hematologic cancer	9.05e-07	1.03e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—MAPK8—hematologic cancer	9.05e-07	1.03e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—MYC—hematologic cancer	9.05e-07	1.03e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling by GPCR—AKT1—hematologic cancer	9.03e-07	1.02e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—TGFB1—hematologic cancer	9.02e-07	1.02e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—EP300—hematologic cancer	9.01e-07	1.02e-05	CbGpPWpGaD
Imipramine—CYP2E1—Metabolism—EP300—hematologic cancer	9.01e-07	1.02e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—EP300—hematologic cancer	9e-07	1.02e-05	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	8.99e-07	1.02e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—EP300—hematologic cancer	8.97e-07	1.02e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—EP300—hematologic cancer	8.94e-07	1.01e-05	CbGpPWpGaD
Imipramine—ABCB1—Metabolism—PIK3R1—hematologic cancer	8.92e-07	1.01e-05	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—NCOR1—hematologic cancer	8.91e-07	1.01e-05	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—GSTM1—hematologic cancer	8.91e-07	1.01e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—SRC—hematologic cancer	8.91e-07	1.01e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—MAPK3—hematologic cancer	8.9e-07	1.01e-05	CbGpPWpGaD
Imipramine—CYP2D6—Metabolism—PIK3CD—hematologic cancer	8.9e-07	1.01e-05	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—PIK3CA—hematologic cancer	8.86e-07	1e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—EP300—hematologic cancer	8.85e-07	1e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—EP300—hematologic cancer	8.83e-07	1e-05	CbGpPWpGaD
Imipramine—CYP2D6—Metabolism—ALB—hematologic cancer	8.78e-07	9.96e-06	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—SRC—hematologic cancer	8.77e-07	9.94e-06	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—SRC—hematologic cancer	8.75e-07	9.92e-06	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—SRC—hematologic cancer	8.72e-07	9.88e-06	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—HRAS—hematologic cancer	8.72e-07	9.88e-06	CbGpPWpGaD
Imipramine—CHRM4—Signaling Pathways—IL6—hematologic cancer	8.71e-07	9.87e-06	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—SRC—hematologic cancer	8.69e-07	9.85e-06	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—VEGFA—hematologic cancer	8.68e-07	9.84e-06	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—MYC—hematologic cancer	8.66e-07	9.82e-06	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—TGFB1—hematologic cancer	8.64e-07	9.79e-06	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—SRC—hematologic cancer	8.61e-07	9.76e-06	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—STAT3—hematologic cancer	8.59e-07	9.74e-06	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—SRC—hematologic cancer	8.58e-07	9.73e-06	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—PIK3CG—hematologic cancer	8.57e-07	9.72e-06	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—NRAS—hematologic cancer	8.57e-07	9.72e-06	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—TP53—hematologic cancer	8.57e-07	9.71e-06	CbGpPWpGaD
Imipramine—SLC22A1—Metabolism—PIK3CA—hematologic cancer	8.56e-07	9.7e-06	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—VEGFA—hematologic cancer	8.54e-07	9.68e-06	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—VEGFA—hematologic cancer	8.52e-07	9.66e-06	CbGpPWpGaD
Imipramine—HTR6—Signaling Pathways—AKT1—hematologic cancer	8.52e-07	9.66e-06	CbGpPWpGaD
Imipramine—HTR7—Signaling Pathways—AKT1—hematologic cancer	8.51e-07	9.65e-06	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—VEGFA—hematologic cancer	8.49e-07	9.63e-06	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—VEGFA—hematologic cancer	8.47e-07	9.6e-06	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—STAT3—hematologic cancer	8.45e-07	9.58e-06	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—STAT3—hematologic cancer	8.44e-07	9.56e-06	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—NRAS—hematologic cancer	8.43e-07	9.56e-06	CbGpPWpGaD
Imipramine—CYP2C19—Metabolism—PIK3CB—hematologic cancer	8.43e-07	9.56e-06	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—NRAS—hematologic cancer	8.42e-07	9.54e-06	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—STAT3—hematologic cancer	8.41e-07	9.53e-06	CbGpPWpGaD
Imipramine—CYP2D6—Metabolism—PIK3R1—hematologic cancer	8.4e-07	9.52e-06	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—KRAS—hematologic cancer	8.4e-07	9.52e-06	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—NRAS—hematologic cancer	8.39e-07	9.51e-06	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—VEGFA—hematologic cancer	8.38e-07	9.5e-06	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—STAT3—hematologic cancer	8.38e-07	9.5e-06	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—NRAS—hematologic cancer	8.36e-07	9.48e-06	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—VEGFA—hematologic cancer	8.36e-07	9.48e-06	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—KRAS—hematologic cancer	8.36e-07	9.48e-06	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—IL6—hematologic cancer	8.34e-07	9.46e-06	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—STAT3—hematologic cancer	8.3e-07	9.41e-06	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—NRAS—hematologic cancer	8.28e-07	9.39e-06	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—STAT3—hematologic cancer	8.28e-07	9.38e-06	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—NRAS—hematologic cancer	8.26e-07	9.36e-06	CbGpPWpGaD
Imipramine—ABCB1—Metabolism—PIK3CB—hematologic cancer	8.23e-07	9.33e-06	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—MAPK3—hematologic cancer	8.21e-07	9.31e-06	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—HRAS—hematologic cancer	8.19e-07	9.29e-06	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—MAPK3—hematologic cancer	8.08e-07	9.16e-06	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—MAPK3—hematologic cancer	8.06e-07	9.14e-06	CbGpPWpGaD
Imipramine—CHRM4—Signaling Pathways—AKT1—hematologic cancer	8.04e-07	9.11e-06	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—MAPK3—hematologic cancer	8.03e-07	9.11e-06	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—MAPK3—hematologic cancer	8.01e-07	9.08e-06	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—KRAS—hematologic cancer	8e-07	9.07e-06	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—MYC—hematologic cancer	7.98e-07	9.05e-06	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—TGFB1—hematologic cancer	7.96e-07	9.03e-06	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—CREBBP—hematologic cancer	7.95e-07	9.01e-06	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—MAPK3—hematologic cancer	7.93e-07	8.99e-06	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—MAPK3—hematologic cancer	7.91e-07	8.97e-06	CbGpPWpGaD
Imipramine—CHRM3—Metabolism—PIK3CA—hematologic cancer	7.91e-07	8.96e-06	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—MTHFR—hematologic cancer	7.88e-07	8.93e-06	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—MYC—hematologic cancer	7.86e-07	8.91e-06	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—IL6—hematologic cancer	7.84e-07	8.89e-06	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—MYC—hematologic cancer	7.84e-07	8.89e-06	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—TGFB1—hematologic cancer	7.84e-07	8.88e-06	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—TGFB1—hematologic cancer	7.82e-07	8.86e-06	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—MYC—hematologic cancer	7.81e-07	8.86e-06	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—TGFB1—hematologic cancer	7.79e-07	8.84e-06	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—MYC—hematologic cancer	7.79e-07	8.83e-06	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—TGFB1—hematologic cancer	7.77e-07	8.81e-06	CbGpPWpGaD
Imipramine—CYP2D6—Metabolism—PIK3CB—hematologic cancer	7.76e-07	8.79e-06	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—PIK3CA—hematologic cancer	7.72e-07	8.75e-06	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—MYC—hematologic cancer	7.71e-07	8.74e-06	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—AKT1—hematologic cancer	7.7e-07	8.72e-06	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—TGFB1—hematologic cancer	7.69e-07	8.72e-06	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—MYC—hematologic cancer	7.69e-07	8.72e-06	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—PIK3CA—hematologic cancer	7.68e-07	8.71e-06	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—TGFB1—hematologic cancer	7.67e-07	8.7e-06	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—PIK3CD—hematologic cancer	7.54e-07	8.55e-06	CbGpPWpGaD
Imipramine—CYP3A7—Metabolism—AKT1—hematologic cancer	7.51e-07	8.52e-06	CbGpPWpGaD
Imipramine—SLC22A2—Metabolism—AKT1—hematologic cancer	7.5e-07	8.5e-06	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—TP53—hematologic cancer	7.47e-07	8.47e-06	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—ALB—hematologic cancer	7.44e-07	8.44e-06	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—TP53—hematologic cancer	7.43e-07	8.42e-06	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—KRAS—hematologic cancer	7.38e-07	8.36e-06	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—PIK3CA—hematologic cancer	7.35e-07	8.33e-06	CbGpPWpGaD
Imipramine—CYP2C19—Metabolism—PTEN—hematologic cancer	7.29e-07	8.26e-06	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—KRAS—hematologic cancer	7.26e-07	8.23e-06	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—KRAS—hematologic cancer	7.24e-07	8.21e-06	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—AKT1—hematologic cancer	7.24e-07	8.2e-06	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—KRAS—hematologic cancer	7.22e-07	8.18e-06	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—KRAS—hematologic cancer	7.2e-07	8.16e-06	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—HRAS—hematologic cancer	7.14e-07	8.1e-06	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—KRAS—hematologic cancer	7.13e-07	8.08e-06	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—PIK3R1—hematologic cancer	7.12e-07	8.07e-06	CbGpPWpGaD
Imipramine—ABCB1—Metabolism—PTEN—hematologic cancer	7.11e-07	8.06e-06	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—TP53—hematologic cancer	7.11e-07	8.06e-06	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—KRAS—hematologic cancer	7.11e-07	8.06e-06	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—HRAS—hematologic cancer	7.1e-07	8.05e-06	CbGpPWpGaD
Imipramine—SLC22A1—Metabolism—AKT1—hematologic cancer	6.99e-07	7.93e-06	CbGpPWpGaD
Imipramine—CYP2C19—Metabolism—EP300—hematologic cancer	6.95e-07	7.88e-06	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—IL6—hematologic cancer	6.84e-07	7.75e-06	CbGpPWpGaD
Imipramine—CYP2B6—Metabolism—PIK3CA—hematologic cancer	6.8e-07	7.71e-06	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—HRAS—hematologic cancer	6.8e-07	7.71e-06	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—IL6—hematologic cancer	6.8e-07	7.71e-06	CbGpPWpGaD
Imipramine—ABCB1—Metabolism—EP300—hematologic cancer	6.78e-07	7.69e-06	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—PIK3CA—hematologic cancer	6.78e-07	7.68e-06	CbGpPWpGaD
Imipramine—CYP2D6—Metabolism—PTEN—hematologic cancer	6.7e-07	7.6e-06	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—PIK3CA—hematologic cancer	6.67e-07	7.56e-06	CbGpPWpGaD
Imipramine—CYP2E1—Metabolism—PIK3CA—hematologic cancer	6.66e-07	7.55e-06	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—PIK3CA—hematologic cancer	6.65e-07	7.54e-06	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—PIK3CA—hematologic cancer	6.63e-07	7.52e-06	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—PIK3CG—hematologic cancer	6.62e-07	7.5e-06	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—PIK3CA—hematologic cancer	6.61e-07	7.5e-06	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—PIK3CB—hematologic cancer	6.57e-07	7.45e-06	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—TP53—hematologic cancer	6.56e-07	7.43e-06	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—PIK3CA—hematologic cancer	6.55e-07	7.42e-06	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—PIK3CA—hematologic cancer	6.53e-07	7.4e-06	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—IL6—hematologic cancer	6.51e-07	7.38e-06	CbGpPWpGaD
Imipramine—CHRM3—Metabolism—AKT1—hematologic cancer	6.46e-07	7.32e-06	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—TP53—hematologic cancer	6.45e-07	7.31e-06	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—TP53—hematologic cancer	6.44e-07	7.3e-06	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—TP53—hematologic cancer	6.42e-07	7.27e-06	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—TP53—hematologic cancer	6.4e-07	7.25e-06	CbGpPWpGaD
Imipramine—CYP2D6—Metabolism—EP300—hematologic cancer	6.39e-07	7.25e-06	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—TP53—hematologic cancer	6.33e-07	7.18e-06	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—TP53—hematologic cancer	6.32e-07	7.16e-06	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—AKT1—hematologic cancer	6.31e-07	7.15e-06	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—AKT1—hematologic cancer	6.27e-07	7.11e-06	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—HRAS—hematologic cancer	6.27e-07	7.11e-06	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—HRAS—hematologic cancer	6.17e-07	6.99e-06	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—HRAS—hematologic cancer	6.16e-07	6.98e-06	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—HRAS—hematologic cancer	6.14e-07	6.96e-06	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—CREBBP—hematologic cancer	6.14e-07	6.96e-06	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—HRAS—hematologic cancer	6.12e-07	6.93e-06	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—HRAS—hematologic cancer	6.06e-07	6.87e-06	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—HRAS—hematologic cancer	6.04e-07	6.85e-06	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—AKT1—hematologic cancer	6.01e-07	6.81e-06	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—IL6—hematologic cancer	6e-07	6.8e-06	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—IL6—hematologic cancer	5.91e-07	6.69e-06	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—IL6—hematologic cancer	5.89e-07	6.68e-06	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—IL6—hematologic cancer	5.87e-07	6.66e-06	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—IL6—hematologic cancer	5.85e-07	6.64e-06	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—PIK3CD—hematologic cancer	5.82e-07	6.59e-06	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—IL6—hematologic cancer	5.8e-07	6.57e-06	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—IL6—hematologic cancer	5.78e-07	6.55e-06	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—ALB—hematologic cancer	5.74e-07	6.51e-06	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—PTEN—hematologic cancer	5.68e-07	6.44e-06	CbGpPWpGaD
Imipramine—CYP2B6—Metabolism—AKT1—hematologic cancer	5.56e-07	6.3e-06	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—AKT1—hematologic cancer	5.54e-07	6.28e-06	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—PIK3R1—hematologic cancer	5.49e-07	6.23e-06	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—AKT1—hematologic cancer	5.45e-07	6.18e-06	CbGpPWpGaD
Imipramine—CYP2E1—Metabolism—AKT1—hematologic cancer	5.44e-07	6.17e-06	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—AKT1—hematologic cancer	5.44e-07	6.16e-06	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—AKT1—hematologic cancer	5.42e-07	6.14e-06	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—EP300—hematologic cancer	5.41e-07	6.14e-06	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—AKT1—hematologic cancer	5.4e-07	6.12e-06	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—AKT1—hematologic cancer	5.35e-07	6.06e-06	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—AKT1—hematologic cancer	5.33e-07	6.05e-06	CbGpPWpGaD
Imipramine—CYP2C19—Metabolism—PIK3CA—hematologic cancer	5.14e-07	5.83e-06	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—PIK3CB—hematologic cancer	5.07e-07	5.75e-06	CbGpPWpGaD
Imipramine—ABCB1—Metabolism—PIK3CA—hematologic cancer	5.02e-07	5.69e-06	CbGpPWpGaD
Imipramine—CYP2D6—Metabolism—PIK3CA—hematologic cancer	4.73e-07	5.36e-06	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—PTEN—hematologic cancer	4.38e-07	4.97e-06	CbGpPWpGaD
Imipramine—CYP2C19—Metabolism—AKT1—hematologic cancer	4.2e-07	4.76e-06	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—EP300—hematologic cancer	4.18e-07	4.74e-06	CbGpPWpGaD
Imipramine—ABCB1—Metabolism—AKT1—hematologic cancer	4.1e-07	4.65e-06	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—PIK3CA—hematologic cancer	4.01e-07	4.54e-06	CbGpPWpGaD
Imipramine—CYP2D6—Metabolism—AKT1—hematologic cancer	3.86e-07	4.38e-06	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—AKT1—hematologic cancer	3.27e-07	3.71e-06	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—PIK3CA—hematologic cancer	3.09e-07	3.5e-06	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—AKT1—hematologic cancer	2.53e-07	2.86e-06	CbGpPWpGaD
